MO · 10-Q · 2026Q3 · Full report
FDA Tobacco Product Regulation
ALTRIA GROUP, INC. · 2026-10-29 · Importance 34 · Surprise 42 · In source text
In May 2026, the FDA issued guidance on enforcement for certain e-vapor and oral nicotine pouch products with pending PMTAs, generally deprioritizing enforcement for specified products undergoing scientific review or qualifying pending supplemental applications. The guidance preserves case-by-case enforcement and excludes, among others, products appealing to youth or presenting greater public-health or safety concerns. Public health organizations challenged the guidance in the U.S. District Court for the District of Maryland in July 2026, and Helix and NJOY moved to intervene in support of the FDA in October 2026.
Key facts
- NJOY ACE is subject to ITC exclusion and cease-and-desist orders prohibiting importation and sale in the United States; NJOY Daily is not subject to those orders. source
- As of October 26, 2026, Middleton had received FDA marketing orders or exemptions covering over 99% of its cigar product volume. source
- Altria incurred total NJOY Transaction costs of $181 million, primarily related to the ITC exclusion and cease-and-desist orders and patent infringement lawsuits, offset by $81 million of insurance recoveries. source
- In May 2026, the FDA issued guidance on enforcement for certain e-vapor and oral nicotine pouch products with pending PMTAs; it generally will not prioritize enforcement against products undergoing scientific review or certain pending Supplemental PMTAs. source
- In July 2026, several public health organizations challenged the FDA’s May 2026 guidance in federal court in Maryland; in October 2026, Helix and NJOY moved to intervene in support of the FDA. source
- In December 2025, the FDA issued marketing orders for on! PLUS tobacco, mint, and wintergreen oral nicotine pouches in 6 mg and 9 mg nicotine levels. source
- In August 2026, the FDA issued marketing orders for on! oral nicotine pouches in autumn spice, rich berry, and cappuccino flavors in 2 mg and 4 mg nicotine levels. source
- In September 2025, the FDA launched a pilot program intended to streamline review of PMTAs for selected oral nicotine pouch products. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -3.0% | Altria incurred total NJOY Transaction costs of $181 million, primarily related to the ITC exclusion and cease-and-desist orders and… |
| operating_income | positive | realized | +1.3% | Altria incurred total NJOY Transaction costs of $181 million, primarily related to the ITC exclusion and cease-and-desist orders and… |
| revenue | negative | realized | — | NJOY ACE is subject to ITC exclusion and cease-and-desist orders prohibiting importation and sale in the United States; NJOY Daily is not… |